A detailed history of Stansberry Asset Management, LLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Stansberry Asset Management, LLC holds 83,937 shares of ABCL stock, worth $247,614. This represents 0.03% of its overall portfolio holdings.

Number of Shares
83,937
Previous 88,410 5.06%
Holding current value
$247,614
Previous $261,000 16.86%
% of portfolio
0.03%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.39 - $3.49 $10,690 - $15,610
-4,473 Reduced 5.06%
83,937 $217,000
Q2 2024

Aug 13, 2024

SELL
$2.73 - $4.73 $13,316 - $23,072
-4,878 Reduced 5.23%
88,410 $261,000
Q1 2024

May 14, 2024

SELL
$4.29 - $5.97 $82,277 - $114,498
-19,179 Reduced 17.05%
93,288 $422,000
Q3 2023

Nov 14, 2023

BUY
$4.6 - $7.95 $45,043 - $77,846
9,792 Added 9.54%
112,467 $517,000
Q2 2023

Aug 11, 2023

BUY
$5.66 - $7.59 $6,441 - $8,637
1,138 Added 1.12%
102,675 $663,000
Q1 2023

May 12, 2023

BUY
$7.31 - $11.18 $9,948 - $15,215
1,361 Added 1.36%
101,537 $765,000
Q4 2022

Feb 13, 2023

BUY
$9.48 - $14.52 $19,206 - $29,417
2,026 Added 2.06%
100,176 $1.01 Million
Q3 2022

Nov 14, 2022

SELL
$9.2 - $13.68 $21,758 - $32,353
-2,365 Reduced 2.35%
98,150 $971,000
Q2 2022

Aug 15, 2022

SELL
$5.72 - $10.65 $14,002 - $26,071
-2,448 Reduced 2.38%
100,515 $1.07 Million
Q1 2022

May 16, 2022

BUY
$7.46 - $14.14 $52,578 - $99,658
7,048 Added 7.35%
102,963 $1 Million
Q4 2021

Feb 14, 2022

BUY
$12.99 - $17.73 $739,663 - $1.01 Million
56,941 Added 146.1%
95,915 $1.37 Million
Q3 2021

Nov 15, 2021

BUY
$14.85 - $21.34 $578,763 - $831,705
38,974 New
38,974 $781,000

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $841M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Stansberry Asset Management, LLC Portfolio

Follow Stansberry Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stansberry Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stansberry Asset Management, LLC with notifications on news.